What long-acting oral diltiazem (Cardizem) formulations are available?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Long-Acting Oral Diltiazem Formulations

Long-acting oral diltiazem is available as extended-release (ER) or controlled-delivery (CD) formulations, dosed once daily at 120-540 mg, with slow-release preparations also available for divided dosing at 120-360 mg daily. 1

Available Formulations

Extended-Release/Controlled-Delivery (Once-Daily)

  • Cardizem CD (controlled-delivery): Once-daily formulation designed for 24-hour controlled delivery, available in doses ranging from 120 mg to 540 mg daily 2, 3
  • Standard dosing range: 120-360 mg once daily for most indications, with doses up to 540 mg/day studied and found safe for hypertension 1, 3, 4
  • Minimum effective dose: 120 mg daily represents the starting dose for extended-release formulations 5, 2
  • Therapeutic range: 180-420 mg once daily for hypertension and angina, with peak efficacy typically at 240-360 mg daily 2, 4

Slow-Release Formulations (Divided Dosing)

  • Slow-release tablets: Available for divided dosing at 120-360 mg daily in 2-3 divided doses 1
  • Onset of action: 2-4 hours with maintenance dosing 1

Key Pharmacokinetic Considerations

Nonlinear Pharmacokinetics

  • Dose-dependent absorption: Diltiazem exhibits nonlinear disposition, with disproportionate increases in drug exposure at higher doses 6
  • Therapeutic drug levels: Doses ≥240 mg/day provide trough blood levels within the therapeutic range (≥40 ng/mL) 4
  • 24-hour efficacy: Extended-release formulations maintain consistent blood levels and blood pressure control throughout the dosing interval 3, 4

Chronotherapeutic Dosing

  • Evening dosing advantage: Evening-dosed extended-release diltiazem provides greater morning blood pressure reduction, when cardiovascular events cluster, compared to morning dosing 3
  • Circadian harmony: The long-acting formulation is designed with chronodynamics that align with diurnal blood pressure variation 3

Administration Guidelines

Formulation-Specific Instructions

  • Extended-release capsules: Must be swallowed whole; cannot be split, crushed, or chewed 5, 2
  • Immediate-release tablets (30-120 mg): May be swallowed whole, crushed, or chewed, but should not be split 7

Dose Titration

  • Starting dose: 120-180 mg once daily for extended-release formulations 2, 4
  • Titration interval: Increase gradually at 1-2 week intervals based on response 2, 4
  • Maximum dose: 360-540 mg once daily, with 540 mg/day demonstrated as safe and well-tolerated 2, 3, 4

Clinical Efficacy Data

Transition from IV to Oral

  • Conversion protocol: Oral long-acting diltiazem (180-360 mg/day) maintains heart rate control in 77% of patients when transitioning from IV diltiazem, with IV discontinued 4 hours after first oral dose 8
  • Median effective dose: 300 mg/day of oral diltiazem CD for rate control in atrial fibrillation 8

Blood Pressure Control

  • Dose-response relationship: Clear dose-dependent blood pressure reduction with doses ≥240 mg/day, with incremental benefit up to 540 mg/day 3, 4
  • 24-hour coverage: Ambulatory blood pressure monitoring confirms consistent reductions throughout the dosing interval 4

Important Caveats

  • Hepatic/renal impairment: No specific dosing data available; titrate with particular caution in these populations 7
  • Drug interactions: Diltiazem is both a CYP3A4 substrate and moderate inhibitor, requiring caution with numerous medications including apixaban, cyclosporine, and statins 2
  • Contraindications: Avoid in second/third-degree AV block without pacemaker, decompensated heart failure, severe LV dysfunction, and WPW syndrome with atrial fibrillation 1, 2
  • Combination therapy caution: Use extreme caution when combining with beta-blockers due to risk of significant bradyarrhythmias and heart block 2

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.